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9 Abstract
10 Voltage-gated calcium channels type 2.2 (CaV2.2) are activated by action potentials 
11 at presynaptic terminals, and their calcium current induces neurotransmitter release. In this 
12 context, regulating CaV2.2 is critical, and one of the most important mechanisms for doing 
13 so is through is G protein-coupled receptor (GPCR) activity. Two such GPCRs are the 
14 ghrelin (GHSR) and the dopamine type 2 (D2R) receptors. We previously demonstrated that 
15 constitutive GHSR activity reduces CaV2.2 forward trafficking and that ghrelin-induced 
16 GHSR activity inhibits CaV2.2 currents. On the other hand, dopamine-induced D2R activity 
17 also inhibits CaV2.2 currents. It has been recently shown that D2R and GHSR form 
18 heteromers in hypothalamic neurons. This interaction profoundly changes the signaling 
19 cascades activated by dopamine and is necessary for dopamine-dependent anorexia. Here 
20 we explored how D2R-GHSR co-expression in HEK293T cells modulates the effect that 
21 each GPCR has on CaV2.2. We found that D2R-GHSR co-expression reduces the inhibition 
22 of CaV2.2 currents by agonist-induced D2R activation and added a new source of basal 
23 CaV2.2 current inhibition to the one produced by GHSR solely expression. We investigated 
24 the signaling cascades implicated and found that constitutive GHSR activity, Gq protein and 
25 Gβγ subunit play a critical role in these altered effects. Moreover, we found that the effect of 
26 D2R agonist on native calcium currents in hypothalamic neurons is reduced when both D2R 
27 and GHSR are over-expressed. In summary, our results allow us to propose a novel 
28 mechanism for controlling CaV2.2 currents involving the co-expression of two physiologically 
29 relevant GPCRs.
30 Keywords
31 Dopamine, ghrelin, hypothalamus, calcium channels, G protein, heteromers.
32
33 Introduction
34 G protein-coupled receptors (GPCRs) are important for controlling neuronal 
35 functions [1-3]. The cellular effects of a given GPCR vary based on neuronal type and 
36 environmental conditions. Thus, defining the main G protein subtype that is coupled and the 
37 downstream intracellular pathways that are activated is insufficient to explain the diverse 
38 functions of a given GPCR. In this context, understanding non-canonical properties of 
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1 GPCRs, which critically change their global effect, can help to illuminate complex GPCR 
2 behavior. Among these non-classical properties are constitutively active states [4-6], 
3 promiscuous G protein activation by different natural and pharmacological agonists [7-9], 
4 and GPCR homo- and heteromerization [10-12].
5 Several GPCR heteromers have been described with the advance of biochemical 
6 and imaging techniques such as FRET (Förster Resonance Energy Transfer) and BRET 
7 (bioluminescence resonance energy transfer) [13]. The GPCRs more prone to form 
8 heteromers include the dopamine receptors and the ghrelin receptor (GHSR) [14, 15]. A 
9 physiologically relevant example of this non-canonical GPCR behavior is the dopamine type 
10 2 receptor (D2R) and GHSR heteromerization in hypothalamic neurons, where their 
11 interaction is required for the anorexigenic effect of D2R activation by agonists [12]. When 
12 both receptors are co-expressed on the same neuron, the dopamine-induced D2R signaling 
13 pathway activation switches from adenylate cyclase (AC) inhibition to calcium mobilization 
14 from internal stores in a Gβγ- and phospholipase C (PLC)-dependent manner [12, 16]. An 
15 important question that arises from these observations is: does D2R-GHSR interaction 
16 impact other neuronal targets?
17 D2R and GHSR signaling modulate presynaptic CaV2 channels, which are key 
18 effectors for their actions. In particular, the activation of these two GPCRs independently 
19 inhibits presynaptic CaV2.2 subtype, affecting neurotransmitter release [5, 17-19]. 
20 Dopamine-induced D2R activation reduces CaV2.2 currents in a Gi/o protein dependent 
21 manner, while ghrelin-induced GHSR activation acts through its coupling to Gq protein [5, 
22 20]. On the other hand, we have previously demonstrated that constitutive GHSR activity, 
23 through the Gi/o signaling pathway, affects CaV2.2 trafficking to the plasma membrane and 
24 consequently reduces CaV2.2 calcium currents [21]. Here, we aimed to evaluate if D2R and 
25 GHSR co-expression differentially impacts on CaV2.2 current modulation.
26
27 Results and discussion
28 First we explored the effect of consecutive applications of D2R and GHSR agonists 
29 (quinpirole 10 µM and ghrelin 0.5 µM) on native CaV currents in hypothalamic cultured 
30 neurons, where D2R-GHSR co-expression has been previously reported [12]. For both 
31 agonists, we observed a range of inhibition on CaV currents, as expected for a native system 
32 [5, 17]. Specifically, we noticed that neurons with a large inhibitory response to quinpirole 
33 exhibited a mild inhibitory response to ghrelin (see example a in figure 1). Conversely, 
34 neurons that were less sensitive to quinpirole displayed a large response to ghrelin (see 
35 example b in figure 1). Quinpirole and ghrelin effects were reversible upon washout as CaV 
36 currents were fully recovered (data not shown) were reversible upon washout as Cav 
37 currents. We estimated the Spearman's correlation coefficient between the degree of 
38 quinpirole- and ghrelin-induced inhibitions and found a significant inverse correlation (figure 
39 1). Assuming that larger inhibitory effects are mainly due to higher receptor expression levels 
40 and based on the correlation between the effects of ghrelin and quinpirole, we hypothesize 
41 that changes in CaV current inhibition due to D2R and/or GHSR agonists is a new functional 
42 output of D2R-GHSR heteromerization in hypothalamic neurons.
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2 We next evaluated this correlation in a more controlled manner by over-expressing 
3 D2R and GHSR in hypothalamic cultured neurons. We used a lentiviral system with a high 
4 efficiency of transduction, resulting in homogeneous expression of each GPCR within the 
5 neuronal population, and evaluated the inhibitory effect of quinpirole and ghrelin in neurons 
6 over-expressing D2R, GHSR, or both GPCRs. Under these experimental conditions, we 
7 expected that over-expressing one receptor, but not the other, would increase the fraction 
8 of over-expressed receptor detached from the other. Conversely, we expected that the 
9 simultaneous over-expression of both receptors would increase the fraction of D2R-GHSR 
10 heteromers. As we show in figure 2A, the inhibitory effect of ghrelin on CaV currents was 
11 larger in neurons over-expressing GHSR than in neurons over-expressing D2R. Moreover, 
12 the effect of ghrelin in neurons co-expressing both GPCRs was not significantly different 
13 from neurons expressing GHSR alone. For quinpirole, we observed a larger effect in 
14 neurons over-expressing D2R alone compared to neurons expressing GHSR only (figure 
15 2B). Importantly, we found a significant reduction in the inhibitory effect of quinpirole in 
16 neurons co-expressing D2R and GHSR. This result indicates that D2R-GHSR co-expression 
17 modulates quinpirole-mediated inhibition of CaV currents, while ghrelin-mediated inhibition 
18 remains unaffected. We next plotted the percent inhibition by quinpirole and ghrelin for the 
19 sets of neurons in which we were able to evaluate the effect of both agonists, as we did 
20 previously for uninfected neurons (figure 1). Figure 2C displays a lack of correlation for each 
21 group and reveals that the data can be segregated into two groups: neurons over-expressing 
22 D2R (squares), which are highly sensitive to quinpirole and lowly sensitive to ghrelin; and 
23 neurons over-expressing either GHSR or both GPCRs (triangles and circles, respectively), 
24 which have similar sensitivity to quinpirole and ghrelin. These results support the idea that 
25 D2R-GHSR co-expression alters the agonist-induced D2R signaling pathway that inhibits 
Figure 1. Barium current inhibition 
by quinpirole and ghrelin are 
inversely correlated in 
hypothalamic neurons. Examples 
of barium current (IBa) traces before 
and after consecutive applications of 
quinpirole (10 µM, +Quin) and ghrelin 
(0.5 µM, +Ghre) from 2 cultured 
mouse embryonic hypothalamic 
neurons named a and b. Correlation 
between the percent inhibition of IBa 
by quinpirole versus ghrelin was 
calculated (Spearman`s correlation 
coefficient, r, and P value indicated). 
The best lineal fit line is also 
displayed (r2=0.6615, slope=-0.7633 
P=0.0141 versus zero).
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1 native CaV currents, while agonist-induced GHSR inhibition of CaV currents remains 
2 unaffected. This is in agreement with previous data from Kern et al. showing that the co-
3 expression of D2R and GHSR modifies quinpirole signaling cascade in a hypothalamic 
4 neuronal cell line [12]. 
5
6 Figure 2. Simultaneous over-expression of D2R and GHSR in hypothalamic neurons 
7 reduces the inhibitory effect of quinpirole on barium currents. A. Representative traces 
8 (top) of normalized barium current (IBa) from cultured mouse embryonic hypothalamic 
9 neurons transduced by lentivirus with D2R (+D2R, n=10), GHSR (+GHSR, n=8), or both 
10 receptors (+D2R +GHSR, n=6), before and after ghrelin application (0.5 µM, +Ghre). Bars 
11 (bottom) represent average percent inhibition of IBa by ghrelin. Statistical significance was 
12 evaluated by Kruskal-Wallis and Dunn’s post-test. B. Representative traces (top) of IBa from 
13 cultured mouse embryonic hypothalamic neurons transduced by lentivirus with GHSR 
14 (+GHSR, n=8), D2R (+D2R, n=13), or both receptors (+D2R +GHSR, n=6) before and after 
15 quinpirole (10 µM, +Quin) application. Bars (bottom) represent average percent inhibition of 
16 IBa by quinpirole. Statistical significance was evaluated by Kruskal-Wallis and Dunn’s post-
17 test. C. Scatter plots of the percent inhibition of IBa by quinpirole versus ghrelin, calculated 
18 from hypothalamic neurons transduced by lentivirus with D2R (squares, n=10), GHSR 
19 (triangles, n=8), or both receptors (circles, n=6). Empty small symbols represent individual 
20 values. Correlation between the percentage of IBa inhibition by quinpirole and ghrelin was 
21 calculated in each data group and the Spearman`s correlation coefficient, r, and P value 
22 were r=-0.1945 and P=0.5755 for +D2R, r=-0.2143 and P=0.6191 for +GHSR, and r=0.2000 
23 and 0.7139 for +D2R +GHSR not reaching statistical significance in any case. Colored big 
24 symbols represent the average values ± SEM for ghrelin and quinpirole effects.
25 To gain insights of the mechanisms underlying the effects of D2R-GHSR co-expression on 
26 CaV currents, we ran experiments in HEK293T cells expressing the CaV2.2 channel. We 
27 chose this CaV subtype because it is the calcium channel most sensitive to GPCR activity 
28 and is the best studied in terms of its modulation by GHSR and D2R [5, 18-22]. We assayed 
29 the GHSR/D2R interaction in our experimental setting by FRET between GFP (donor) and 
30 mCherry (acceptor) by flow cytometry stimulating with a 488 nm laser. The experiments 
31 were done in HEK293T cells co-expressing GHSR-mCherry, soluble GFP and GHSR-
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1 mCherry (negative control), GHSR-GFP and GHSR-mCherry (positive control see [23]) and 
2 D2R-GFP and GHSR-mCherry. In supplementary figure S1A we showed that in the 
3 condition co-expressing D2R-GFP and GHSR-mCherry the size of cell population with the 
4 highest red fluorescent signal is significantly larger than the negative control condition and 
5 not different from the positive control condition. Moreover we run an internalization assay to 
6 evidence the interaction between GHSR and D2R in our system similar to the report by 
7 Evans et al. [24] and others [25, 26]. In this case, we took advantage of the fact that GHSR 
8 displays ghrelin-mediated internalization and explore if D2R co-internalize with GHSR. As 
9 we show in the supplementary figure S1B we recapitulated the ghrelin mediated 
10 internalization of GHSR by ghrelin as we have shown before [27]. More important, exposing 
11 cells to 0.5 μM ghrelin reduces D2R in the cell surface and increases it in internal 
12 compartments only when GHSR and D2R are co-expressed. Thus we confirmed that GHSR 
13 and D2R interact in our experimental system in vitro. Next we performed patch clamp 
14 experiments in cells co-transfected either D2R, GHSR, or both D2R and GHSR, with each 
15 receptor at a 0.1 molar ratio to the CaV2.2 cDNA. We first tested the percentage of inhibition 
16 of saturating doses of ghrelin (0.5 µM) [5, 28] on whole-cell calcium currents and found no 
17 differences between cells expressing GHSR or both GPCRs (figure 3A). This observation 
18 agrees with our previous data showing the effects of ghrelin on neurons over-expressing 
19 GHSR as compared to neurons expressing both GPCRs. We next assayed the effect of 10 
20 µM dopamine and found that the percentage of current inhibition is reduced by co-
21 expressing GHSR (figure 3B). In order to test whether constitutive GHSR activity is involved 
22 in the reduction of the dopamine-mediated inhibition of CaV2.2 currents, we tested the effect 
23 of 1 µM SPA (substance P analog), a GHSR ligand that stabilizes the receptor in an inactive 
24 state [29] and also uncouples Gq from the receptor [30]. We pre-incubated cells co-
25 expressing D2R and GHSR for 20 hours with SPA and found that this maneuver restored 
26 the inhibitory effect of dopamine to control levels (figure 3B). Moreover, we tested the effects 
27 of dopamine in cells co-expressing D2R and a mutated version of GHSR (GHSRA204E), [5, 
28 31]) that couples to Gq [30] but lacks constitutive activity. We found that the level of CaV2.2 
29 current inhibition by dopamine was equal to that observed in D2R-expressing cells. These 
30 results suggest that constitutive GHSR activity is necessary for the reduced effect of D2R 
31 agonist on CaV2.2 currents in presence of GHSR. However we cannot rule out the possibility 
32 that the rescue of the full inhibitory effect of dopamine by SPA and the GHSR mutant is due 
33 to other causes: the inability of Gq to signal [30], and/or the lower degree of D2R-GHSR 
34 heteromer formation. In this regard, Kern et al. (2012) have proposed that several GHSR 
35 single mutants and SPA incubation modify the GHSR conformational state, preventing its 
36 interaction with D2R [12].
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1 Figure 3. CaV2.2 current inhibition by dopamine-mediated D2R activation is reduced 
2 in presence of GHSR in a GHSR constitutive activity-dependent manner. A. 
3 Representative traces (top) of normalized CaV2.2 calcium currents (ICaV2.2) from HEK293T 
4 cells co-transfected with CaV2.2 and either GHSR (+GHSR, n=7), or GHSR and D2R (+D2R 
5 +GHSR, n=13), before and after ghrelin application (0.5 µM, +Ghre). Bars (bottom) 
6 represent average percent inhibition of ICaV2.2. Statistical significance evaluated by unpaired 
7 t-test, P=0.6049. B. Representative traces (top) of normalized ICaV2.2 from HEK293T cells co-
8 transfected with CaV2.2 and either D2R (+D2R, n=17), or D2R and GHSR pre-incubated 
9 (+D2R +GHSR +SPA, n=4) or not (+D2R +GHSR, n=11) with SPA (1 µM), or D2R and 
10 GHSRA204E (+D2R +A204E, n=8), before and after dopamine application (10 µM, +Dopa). 
11 Statistical significance evaluated by Kruskal-Wallis and Dunn’s post-test (versus +D2R). 
12 In order to determine if the weaker effect of dopamine in presence of GHSR is due 
13 to a reduced affinity of dopamine to D2R and/or to a change in dopamine efficacy, we 
14 performed concentration-response curves for the dopamine effect on HEK293T transfected 
15 with CaV2.2 and either D2R alone or both D2R and GHSR. We found that the co-expression 
16 of GHSR significantly changes the maximum percent current inhibition (figure 4).The EC50 
17 values were in the range of the KD reported for dopamine binding to D2R [32]. The change 
18 in the efficacy of dopamine to inhibit CaV2.2 without a change in its affinity to bind the 
19 receptor suggests that either dopamine acts as a partial agonist when both receptors are 
20 expressed or the intracellular pathways available to D2R are changed in the presence of 
21 GHSR and consequently dopamine would behave as a biased agonist [33]. Interestingly, 
22 we found that the efficacy of dopamine to inhibit CaV2.2 currents was restored to control 
23 values when on HEK293T transfected with CaV2.2 and both D2R and GHSR were pre-
24 incubated with SPA. Thus, this observation suggest that the conformational state of GHSR, 
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1 either per se or due to ability to activate signaling cascades, is important to impair dopamine-
2 mediated inhibition of CaV2.2 currents via D2R.
3
4 Figure 4. The efficacy of dopamine to inhibit CaV2.2 current is reduced when GHSR is 
5 co-expressed. Dopamine concentration (0.01–1000 µM)–response curve of CaV2.2 
6 calcium current inhibition in HEK293T cells co-transfected with CaV2.2 and either D2R 
7 (squares), or D2R and GHSR (circles), pre-incubated or not with SPA (1 µM, +SPA). 
8 Symbols represent the average percent inhibition of calcium current and lines represent the 
9 fitted Hill equation. The n values for each condition are: 89 for +D2R, 48 for +D2R +GHSR 
10 and 28 for +D2R +GHSR +SPA (ranging from 3 to 25 for each data set).The maximum 
11 inhibition for the D2R and GHSR condition (99% confidence interval= 24.65 to 41.22) is 
12 significantly different from the one in the D2R (99% confidence interval= 44.30 to 53.16) and 
13 in the D2R and GHSR in presence of SPA (99% confidence Interval=42.26 to 72.88) 
14 conditions.
15 D2R couples to Gi/o, and the main reported downstream pathways activated by 
16 agonist are: 1) inhibition of adenylate cyclase by Gαi/o, 2) direct activation of inward rectifier 
17 potassium channels (GIRK) [34], and 3) direct inhibition of native CaV2.2 calcium currents 
18 by Gβγ [17]. Dopamine-activated D2R also inhibits CaV2.2 through an additional Gβγ-
19 independent mechanism observed in a heterologous system [20]. Moreover, D2R also 
20 activates PLC in a Gβγ-dependent manner [35]. Kern et al. (2012) have reported that the 
21 D2R and GHSR interaction perturbs the intracellular pathway downstream of Gi/o activation 
22 by dopamine, increasing the activation of PLC and inducing the release of calcium from 
23 intracellular compartments [12]. This effect is mediated by Gq coupled to GHSR [23]. Thus, 
24 we hypothesized that Gq and Gβγ could be involved in the reduction of dopamine-mediated 
25 inhibition of CaV2.2 when D2R and GHSR are co-expressed. We therefore tested the effect 
26 of dopamine in cells co-expressing D2R and GHSR, with or without the addition of a Gq 
27 dominant negative protein (Gq DN) that occludes the downstream effect of Gq without 
28 altering GPCR conformation [36]. We found that the effect of dopamine on CaV2.2 currents 
29 remains unchanged in cells expressing only D2R and Gq DN. In contrast, we observed that 
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1 the degree of CaV2.2 inhibition by dopamine was restored to control value (expressing D2R) 
2 in cells co-expressing D2R, GHSR and Gq DN (figure 5A). Moreover, in order to address the 
3 specificity of GHSR effect on D2R signaling we used an irrelevant Gq protein coupled 
4 receptor. As we show in figure 5B replacing GHSR by the angiotensin II type 1 receptor 
5 (AT1R) failed to modify the dopamine mediated inhibition of CaV2.2 currents. Since it has 
6 been shown before that AT1R activation by angiotensin II inhibits CaV currents [37] here we 
7 also tested the functionality of AT1R and found that angiotensin II 1 µM significantly reduces 
8 the CaV2.2 current in cells expressing AT1R and CaV2.2 (31.53±6.94%, n=3 cells, P=0.0451, 
9 Student’s t-test versus zero). In summary our results suggest that GHSR-mediated 
10 activation of Gq is required for the inhibitory effect of GHSR co-expression on the effects of 
11 dopamine-evoked D2R activity that target CaV2.2.
12
13 Figure 5. The reduced inhibition of CaV2.2 current by dopamine when GHSR is co-
14 expressed depends on Gq protein. A. Representative traces (top) of normalized CaV2.2 
15 calcium current (ICaV2.2) from HEK293T cells co-transfected with CaV2.2, D2R, and either 
16 pcDNA3.1(+) (+D2R, n=6), Gq DN (+D2R +Gq DN, n=11), GHSR (+D2R +GHSR, n=7) or 
17 GHSR and Gq DN (+D2R +GHSR +Gq DN, n=11), before and after dopamine application 
18 (10 µM, +Dopa). Bars (bottom) represent the average percent inhibition of ICaV2.2. Statistical 
19 significance was evaluated by Kruskal-Wallis and Dunn’s post-test (versus +D2R). B. 
20 Representative traces (top) of normalized CaV2.2 calcium current (ICaV2.2) from HEK293T 
21 cells co-transfected with CaV2.2 and D2R (+D2R, n=4), or with D2R and AT1R (+D2R 
22 +AT1R, n=3) before and after dopamine application (10 µM, +Dopa). Bars (bottom) 
23 represent average percent inhibition of ICaV2.2. Statistical significance evaluated by Student´s 
24 t-test.
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1 Next we assayed the involvement of Gβγ subunits to the reduced effect of dopamine 
2 when D2R and GHSR are co-expressed. First, we tested the effect of dopamine on CaV2.2 
3 currents in HEK293T cells co-expressing D2R and MAS-GRK2-ct, a Gβγ buffer peptide [38, 
4 39], and found that buffering Gβγ reduced the effect of dopamine in D2R expressing cells 
5 [20]. Interestingly, the low level of dopamine-mediated CaV2.2 inhibition in cells co-
6 expressing D2R and GHSR remained unchanged when MAS-GRK2-ct was also co-
7 expressed (figure 6). Taken together, our results indicate that the Gβγ role in dopamine 
8 mediated inhibition of CaV2.2 is lost when GHSR is co-expressed. Previous studies have 
9 postulated that activation of one GPCR can transfer its Gβγ subunit to the Gα subunit 
10 coupled to other GPCR, thereby reducing the availability of free Gβγ to exert downstream 
11 effects [40]. On the other hand Kern et al. [12] have shown that D2R and GHSR co-
12 expression leads to a dopamine-induced PLC activation via Gβγ. A putative explanation to 
13 conceal this report with our current data is to postulate that basally active GHSR takes Gβγ 
14 subunits from Gi/o coupled to D2R to activate PLC. In this scenario is possible to think that 
15 the amount of Gβγ available to bind CaV2.2 would be reduced. This idea is in agreement 
16 with other reports demonstrating a close interaction between Gi/o and Gq when D2R and 
17 GHSR are co-expressed [23]. Thus, we hypothesize that constitutive GHSR activity could 
18 reduce the availability of free Gβγ to bind CaV2.2 and consequently impair dopamine-
19 mediated D2R signaling pathways. In summary, the mechanisms involved in GHSR and 
20 D2R interaction seem to be very complex and may imply multiple pathways that differentially 
21 impact on other cellular structures different from CaV2.2. 
22 Figure 6. The reduced inhibition of CaV2.2 current by dopamine when GHSR is co-
23 expressed involves the loss of Gβγ-mediated inhibition of CaV2.2. Representative 
24 traces (top) of normalized ICaV2.2 from HEK293T cells co-transfected with CaV2.2, D2R, and 
25 either pcDNA3.1(+) (+D2R, n=11), MAS-GRK2-ct (+D2R +MAS-GRK2-ct, n=13), GHSR 
26 (+D2R +GHSR, n=13) or GHSR and MAS-GRK2-ct (+D2R +GHSR +MAS-GRK2-ct, n=8) 
Page 9 of 23






























































1 before and after dopamine application (10 µM, +Dopa). Bars (bottom) represent the average 
2 percent of ICaV2.2 inhibition. Statistical significance was evaluated by Kruskal-Wallis and 
3 Dunn’s post-test (versus +D2R). 
4
5 In order to decipher how D2R and GHSR co-expression affects the dopamine- and 
6 ghrelin-evoked inhibition of CaV2.2 we have normalized the size of currents and compared 
7 the percent inhibition for each condition. However, we noticed that the basal CaV2.2 current 
8 densities in pre-normalized data were consistently reduced in cells co-expressing both 
9 receptors. Thus, we decided to investigate whether the co-expression of D2R and GHSR 
10 affects basal CaV2.2 currents. First we run control experiments displayed in supplementary 
11 figure S2 to confirm that manipulating the amount of cDNA for each GPCR plasmid 
12 correlates with GPCR plasma membrane expression. We used GFP- and mOrange-tagged 
13 versions of D2R and GHSR to determine fluorescent signal as a measurement of protein 
14 expression. Once we confirmed this positive correlation we compared the basal current 
15 levels of cells transfected with CaV2.2 alone (as a control) to cells transfected with D2R, 
16 GHSR, or D2R plus GHSR, at the following two different GPCR:CaV2.2 molar ratios: 0.1, as 
17 we used in all our previous experiments, and 0.5. We assayed 0.5 molar ratio because it is 
18 the threshold for basal CaV2.2 current reduction by GHSR constitutive activity as we 
19 described in our previous report [5]. We found a statistically significant reduction in basal 
20 CaV2.2 current only in the conditions co-expressing D2R and GHSR (figure 7). In the case 
21 of cells co-expressing D2R and GHSR in a 0.5 molar ratio, we found undetectable current 
22 levels, indicating more severe effects on CaV2.2 currents at higher GPCR:CaV2.2 molar 
23 ratio. Increasing the cDNA amount for D2R or GHSR alone did not produce statistically 
24 significant changes in the current levels. However, in accordance with our aforementioned 
25 study [5], we found that GHSR expression has a tendency to reduce basal CaV2.2 currents. 
26 D2R expression did not show any clear tendency in changing CaV2.2 current levels, in 
27 agreement with the non-conclusive data regarding D2R constitutive activity [41], though in 
28 the 0.1 D2R:CaV2.2 molar ratio condition, we did observe a slight increase in CaV2.2 current 
29 levels. This tendency of D2R expression to increase current levels at this molar ratio could 
30 be related to a previous report showing that co-expression of D2R increases CaV2.2 surface 
31 expression levels [20]. 
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1 Figure 7. CaV2.2 basal current is reduced by GHSR and D2R co-expression. 
2 Representative traces (top) of CaV2.2 calcium current (ICaV2.2) from HEK293T cells co-
3 transfected with CaV2.2 alone (Control, n=86), D2R, GHSR, or D2R plus GHSR in a 0.1 
4 (+D2R, n=36, +GHSR, n=22, +D2R +GHSR, n=32) or 0.5 GPCR:CaV2.2 molar ratio (+D2R, 
5 n=41, +GHSR, n=14, +D2R +GHSR, n =53). Bars (bottom) represent the average CaV2.2 
6 calcium current levels for each condition. Statistical significance was evaluated by Kruskal-
7 Wallis and Dunn’s post-test (versus Control, * P<0.0001). 
8 Next we explored the possibility that the reduction in basal current density in presence 
9 of both GPCRs could be due to a tonic Gβγ mediated inhibition. We performed experiments 
10 using the same protocol described by Evans et al. [24] to assess the facilitation of current 
11 due to pre-pulse mediated release of Gβγ tonic binding to the CaV2.2. In control conditions 
12 (in absence of GPCRs) we found a reduction of amplitude of CaV2.2 calcium current after 
13 the pre-pulse (I2). We consider this effect mediated by an incomplete recovery from current 
14 inactivation. In cells co-expressing GHSR and CaV2.2 we found I2/I1 values similar to control 
15 indicating lack of Gβγ tonic inhibition in this condition. On the other hand, when we applied 
16 this protocol to cells co-expressing CaV2.2 and D2R the I2/I1 is significantly larger than 
17 control. Moreover, the I2/I1 ratio obtained in cells co-expressing both GPCRs was similar to 
18 control conditions or in presence of only GHSR with CaV2.2. These data indicate that there 
19 is a tonic effect of D2R on CaV2.2 currents that can be release by a strong depolarizing pre-
20 pulse (figure 8A). To confirm the involvement of Gβγ in the basal current facilitation we 
21 repeated the experiments co-expressing the MAS-GRK2-ct, the Gβγ buffer peptide. This 
22 maneuver occluded the pre-pulse mediated current facilitation by D2R co-expression (figure 
23 8B). This tonic inhibition of CaV2.2 currents by D2R co-expression may explain why we failed 
24 to observed the current density increase expected due to the reported D2R mediated rise of 
25 channel protein in the surface [5, 20]. More important, considering that Gβγ mediated 
26 inhibition of CaV2.2 by dopamine is lacking in presence of GHSR we could postulate that the 
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1 loss of tonic inhibition by D2R when co-expressing GHSR could be explained by Gβγ 
2 sequestration by basally active Gq/GHSR complexes. 
3 Figure 8. D2R-mediated Gβγ tonic inhibition of CaV2.2 is lost by GHSR co-expression. 
4 A. Representative traces (left) of CaV2.2 calcium current (ICaV2.2) without (I1) and with (I2) a 
5 pre-pulse at +150 mV from HEK293T cells co-transfected with CaV2.2 alone (Control, n=14), 
6 D2R (+D2R, n=12), GHSR (+GHSR, n=10), or D2R plus GHSR (+D2R +GHSR, n=11) in a 
7 0.1 GPCR:CaV2.2 molar ratio. Bars (right) represent the ratio between the peak current with 
8 and without pre-pulse (I2/I1) for each condition. Statistical significance was evaluated by 
9 ANOVA (versus Control). B. Representative traces (left) of CaV2.2 calcium current (ICaV2.2) 
10 without (I1) and with (I2) a pre-pulse at +150 mV from HEK293T cells co-transfected with 
11 CaV2.2 alone (Control, n=18), D2R (+D2R, n=11), GHSR (+GHSR, n=5), or D2R plus GHSR 
12 (+D2R +GHSR, n=4) and MAS-GRK2-ct in a 0.1 GPCR:CaV2.2 molar ratio. Bars (right) 
13 represent the ratio between the peak current with and without pre-pulse (I2/I1) for each 
14 condition. Statistical significance was evaluated by ANOVA (versus Control). 
15 We next evaluated if the basal CaV2.2 current inhibition caused by D2R-GHSR co-
16 expression involves GHSR constitutive activity as we observed for the reduction in 
17 dopamine evoked CaV2.2 currents. We measured basal CaV2.2 current levels in cells 
18 expressing D2R or both receptors and evaluated the effect of either pre-incubating the cells 
19 with the inverse agonist SPA or replacing GHSR with the mutant GHSRA204E [5, 22, 28, 
20 31]. We found that under both of these conditions, the CaV2.2 current is restored to control 
21 levels (that of D2R-expressing cells) (figure 9). These data indicate that GHSR constitutive 
22 activity is indeed required for the reduction of basal CaV2.2 current by D2R-GHSR co-
23 expression. Next, we explored the intracellular pathways involved in the effect of D2R-GHSR 
24 co-expression on basal CaV2.2 current and found that Gq protein and the Gβγ subunit are 
25 required. Figure 10 displays the basal current reduction caused by D2R-GHSR co-
26 expression and the occlusion of this inhibitory effect by Gq DN or MAS-GRK2-ct. Moreover, 
27 we found that co-expression of AT1R, the GqPCR assayed in figure 5, also failed to modify 
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1 the basal CaV2.2 current when co-expressed with D2R (ICaV2.2 +D2R=22.21±5.49 pA/pF, 
2 n=11 versus ICaV2.2 +D2R+AT1R=24.47±4.19 pA/pF, n=18, P=0.7444, Student’s t-test). Our 
3 previous study showed that GHSR constitutive activity inhibits CaV2.2 currents by a chronic 
4 mechanism that involves Gi/o protein and channel density reduction at the plasma 
5 membrane, without requiring Gq and Gβγ. Here we found that D2R-GHSR co-expression 
6 reduces basal CaV2.2 current at low GHSR expression levels by a novel signaling cascade. 
7 The basal inhibitory effect that we observed involves the same pathways that occlude the 
8 acute dopamine-mediated inhibition of CaV2.2 currents. 
9 Figure 9. Basal reduction of CaV2.2 calcium currents by GHSR and D2R co-expression 
10 requires GHSR constitutive activity. Representative traces (top) of CaV2.2 calcium 
11 current (ICaV2.2) from HEK293T cells co-transfected with CaV2.2 and D2R (+D2R, n=51), and 
12 either GHSR (+GHSR, n=34), GHSR and pre-incubated with SPA (+D2R +GHSR +SPA, 
13 n=17), or GHSRA204E (+D2R +A204E, n=60). Bars (bottom) represent the average ICaV2.2 
14 levels for each condition. Statistical significance was evaluated by Kruskal-Wallis and 
15 Dunn’s post-test (versus +D2R). 
Page 13 of 23































































2 Figure 10. Basal reduction of CaV2.2 calcium currents by GHSR and D2R co-
3 expression requires Gq protein and Gβγ subunit. A. Representative traces (top) of 
4 CaV2.2 calcium current (ICaV2.2) from HEK293T cells co-transfected with CaV2.2 and D2R 
5 (+D2R, n=48), and either GHSR (+D2R +GHSR, n=30), or GHSR and Gq DN (+D2R +GHSR 
6 +Gq DN, n=49). Bars (bottom) represent the average ICaV2.2 levels for each condition. B. 
7 Representative traces (top) of ICaV2.2 from HEK293T cells co-transfected with CaV2.2 and 
8 D2R (+D2R, n=32), and either GHSR (+D2R +GHSR, n=24) or GHSR and MAS-GRK2-ct 
9 (+D2R +GHSR +MAS-GRK2-ct, n=58). Bars (bottom) represent the average ICaV2.2 values 
10 for each condition. Statistical significance was evaluated by Kruskal-Wallis and Dunn’s post-
11 test (versus +D2R).
12 In summary we found a novel mechanism for controlling CaV2.2 currents involving 
13 the co-expression of two physiologically relevant GPCRs. We propose that the Gq protein, 
14 mainly coupled to GHSR, captures Gβγ subunits from the Gi/o protein coupled to D2R and 
15 consequently reduces the ability of Gβγ to binds CaV2.2 and may activates a new signaling 
16 cascade that basally inhibits CaV2.2. Thus, the GHSR-D2R interaction would modify the 
17 Gβγ-dependent effects of D2R and GHSR on CaV2.2. Moreover, the constitutive activation 
18 of GHSR via Gq and Gβγ subunits are required to reduce basal CaV2.2 currents when D2R 
19 is co-expressed. A similar interaction involving Gq and Gβγ has been described in studies 
20 that have also tested for D2R-GHSR heteromers [12, 23]. Both effects of D2R-GHSR co-
21 expression on CaV2.2 currents require GHSR constitutive activity. This observation diverges 
22 from previous reports on the effects of the interaction between these GPCRs [12].
23 We demonstrated that co-expression of D2R and GHSR has an impact on calcium 
24 currents from native and recombinant CaV2.2. Our results suggest that the effect of 
25 dopamine on presynaptic calcium channels would be impaired by the presence of GHSR in 
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1 the presynaptic terminal. Since D2R are located at dopaminergic terminals [42], this effect 
2 could lead to reduced negative feedback and thus to less regulation of dopamine release. 
3 Moreover, since D2R and GHSR are also expressed in other neuronal types, such as 
4 GABAergic [5, 43] and cholinergic neurons [18], this mechanism could also modify the effect 
5 of dopamine on other neurotransmitter release. We also found that D2R-GHSR co-
6 expression in a heterologous system reduced basal CaV2.2 currents. If this mechanism 
7 occurs in neurons, it is plausible that less CaV2.2 current would be available at presynaptic 
8 terminals in neurons co-expressing D2R and GHSR. This mechanism could be important in 
9 a physiological context such as the anorexigenic effect of dopamine observed in 
10 hypothalamic neurons in mice, where the co-expression of D2R-GHSR is required for 
11 calcium release from intracellular stores, leading to transcriptional activation [12]. The 
12 differential modulation of CaV2.2 by dopamine in these neurons could contribute to this effect 
13 by modifying the neuronal communication to appetite control by dopamine.
14 Our study leads to the question of how this novel control of CaV2.2 currents could be 
15 regulated in neurons. One possibility is that regulation occurs by changing the amount of 
16 D2R-GHSR heteromers formed in neurons. This could be modulated by changes in 
17 expression levels of both receptors that have been widely described for both GHSR [44] and 
18 D2R [45]. On the other hand, modifying GHSR constitutive activity also would impact the 
19 mechanism that we described. In this context, the recently reported LEAP2 peptide [46] 
20 gains importance since it has been proposed that it could act as a natural inverse agonist.
21
22 Methods
23 Hypothalamic primary neuronal culture
24 Wild type C57BL/6 mice were housed at IMBICE animal facility in a 12h light-dark 
25 cycle and in a climate-controlled room. Mice were bred with ad libitum access to food and 
26 water. Hypothalamic neurons were removed from mice at embryonic days 15-17 by orienting 
27 brains on the dorsal face and removing the hypothalamus with forceps. Tissue was 
28 processed as described in [22, 47]. These protocols were approved by the ethics committee 
29 of IMBICE in accordance with the Guide for Care and Use of Laboratory Animals of the 
30 National Research Council, USA. 
31
32 Human embryonic kidney (HEK) 293T cell culture
33 HEK293T cells were used in all heterologous expression studies and for lentiviral 
34 production. Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM; Gibco) and 
35 10% of fetal bovine serum was added (FBS; Internegocios). Every time cells achieved 80% 
36 of confluence, they were harvested using citric saline 1X (0.135M KCl, 0.015M sodium 
37 citrate) and plated in 22 mm diameter plates for electrophysiology assays and 100 mm 
38 diameter dishes for lentiviral production. 
39 HEK293T cell transfection 
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1 HEK293T cells were transfected for patch clamp experiments using Lipofectamine 
2 2000 (Invitrogen) and Opti-MEM medium (Invitrogen) according to manufacturer protocols 
3 with 2.5 µg of final cDNA. We used 0.2 µg of an eGFP-containing plasmid to identify 
4 transfected cells. Plated cells were grown for 24 hours before transfection and 24 hours after 
5 transfection to achieve appropriate expression levels.
6 HEK293T cells were transfected for lentiviral production with Polyethylenimine (PEI) 
7 (cat 23966, Polysciences, Inc, USA) and Opti-MEM medium using 20 µg of cDNA / 40 µl of 
8 PEI. Plated cells were grown for 24 hours before transfection and 48 hours after transfection 
9 to allow for lentiviral production.
10 Plasmids containing the following were used for patch clamp experiments in 
11 HEK293T cells: CaV2.2 (#AF055477), CaVβ3 (#M88751), CaVα2δ1 (#AF286488), (all CaV 
12 subunits generously provided by Dr. Diane Lipscombe, Department of Neurosciences, 
13 Brown University, Providence, USA), D2R (MG226860, Origene, donated by Dr. Marcelo 
14 Rubinstein, INGEBI, Buenos Aires, Argentina), GHSR (GHSR, #AY429112, provided by Dr. 
15 J. Marie, Université de Montpellier, Montpellier, France) and AT1R (Donated by Mark 
16 Shapiro, University of Texas Health, San Antonio, USA). In indicated experiments we used 
17 a 0.1 molar ratio of a point mutant of GHSR (GHSRA204E [5]), a Gq dominant-negative 
18 mutant (Gq DN) (Gq-Q209L/D277N; Missouri S&T cDNA Resource Center, Rolla, MO, [36, 
19 48]), or a C-terminal GPCR kinase 2 (MAS-GRK2-ct, gift from S.R. Ikeda, US National 
20 Institutes of Health [38, 39]). CaV subunits were transfected together in every experiment, 
21 each in a 1, 0.1, or 0.5 molar ratio of GPCR:CaV2.2. We fulfilled the amount of cDNA to 1 
22 molar ratio with the empty plasmid pcDNA3.1(+) (Invitrogen), except in the condition using 
23 both GPCRs at 0.5 GPCR:CaV2.2 molar ratio. 
24 For third generation lentiviral system formation, we used a total of 20 µg of cDNA 
25 divided as follows: 3.5 µg of the envelope plasmid pCMV-VSV-G, 4 µg of packaging plasmid 
26 pMDLg/pRRE, 2.5 µg of packaging plasmids pRSV-Rev, and 10 µg of transfer vector 
27 plasmid FU-GHSR-mOrange-W [5] or FU-D2R-GFP-W. 
28 Transduction
29 Lentiviral particles were produced as described in [22]. Lentiviral particles containing 
30 D2R or GHSR vector were generated and used to infect hypothalamic neurons on day 5 of 
31 culture. To over-express both receptors, neurons were infected with both lentiviral particles. 
32 Patch clamp experiments were performed nine days after infection.
33 Drugs 
34 Ghrelin (Global Peptide, cat# PI-G-03) was used as a GHSR agonist. D2R-specific 
35 agonists (−) Quinpirole hydrochloride (Q102, Sigma-Aldrich) and Dopamine hydrochloride 
36 (H8502, Sigma-Aldrich) were used in neurons and HEK293T cells, respectively. [D-Arg1,D-
37 Phe5,D-Trp7,9,Leu11]–substance P analog (SPA, Santa Cruz Biotechnology, Inc.) was 
38 used as a GHSR inverse agonist. Angiotensin II was used in HEK293T cells ( A9525,  
39 Sigma-Aldrich).
40 Electrophysiology
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1 Transfected HEK293T cells were detached from plates using trypsin (0.25 mg/mL). 
2 DMEM + 10% FBS was then added to inhibit trypsin activity, after which cells were rinsed 
3 twice with DMEM. During patch clamp experiments cells were kept at room temperature (23 
4 °C).
5 Whole-cell voltage clamp configuration mode was applied in all experiments. 
6 Depolarizing pulses to 0 mV from a holding potential of -80 mV (for neurons) or to 10 mV 
7 from -100 mV (for HEK293T cells) were used to evoke calcium currents for 30 ms every 10 
8 seconds. For pre-pulse protocol we used the same as [24]. Pipette resistance range was 
9 2-5 MΩ, and series resistances lower than 3 times the pipette resistance were admitted. 
10 Currents were recorded using Axopatch 200 amplifier and PCLAMP8.2 (Molecular 
11 Devices) or an EPC7 amplifier and PatchMaster (HEKA) sampled at 20 kHz and filtered at 
12 10 kHz (-3dB). Cells with a leak current higher than 100 pA at -100 mV were discarded and 
13 leak current was subtracted online using a P/-4 protocol. Perfusion was done by gravity 
14 using 10 ml syringes containing bath solution placed 30 cm over the patch clamp chamber. 
15 The flow rate was ~1 ml/min. Control, quinpirole, ghrelin, dopamine and angiotensin II 
16 containing solutions were applied by different ports connected to the chamber. The liquid 
17 junction potential between the internal and the external solution containing 2 mM CaCl2 (see 
18 below) was ~7.4 mV and between the internal and the external solution containing 10 mM 
19 BaCl2 solution (see below) was ~6.5 mV. These values were measured before experiments 
20 and non-corrected thus all voltages showed were slightly more negative. All recordings were 
21 obtained at room temperature (~24 °C).
22 Neurons were kept in high sodium maintenance solution until whole-cell 
23 configuration was achieved and sodium currents were observed. Once sodium currents 
24 were stabilized, the bath solution was changed to 10 mM barium- and TTX-containing 
25 solution to record barium currents. Once barium currents reached a stable baseline, external 
26 solution with ghrelin or quinpirole was applied in a random order. For recordings in neurons 
27 ground electrode was placed in a separated compartment containing 2 M KCl connected 
28 with the recording chamber containing bath solution by a 2 M KCl-agar salt bridge to avoid 
29 change on junction potentials due to bath exchange during recordings.
30
31 - Internal pipette solution (in mM): 134 CsCl, 10 EGTA, 1 EDTA, 10 HEPES and 4 
32 MgATP (pH 7.2 with CsOH).
33 - External calcium solution (2 mM) for HEK293T cells (in mM): 140 choline chloride, 
34 10 HEPES, 1 MgCl2.6H2O and 2 CaCl2.2H2O (pH 7.3-7.4 with CsOH).
35 - External barium solution (10 mM) for neurons (in mM): 110 choline chloride, 10 
36 HEPES, 10 glucose, 20 tetraethylammonium chloride, 1 MgCl2.6H2O, 10 BaCl2.2H2O and 
37 0.001 tetrodotoxin (TTX; Sigma-Aldrich) (pH 7.3-7.4 with CsOH).
38 - High sodium maintenance solution (135 mM) for neurons (in mM): 10 HEPES, 1.2 
39 MgCl2.6H2O, 2.5 CaCl2.2H2O, 4.7 KCl, 10 glucose and 135 NaCl (pH 7.3-7.4 with NaOH). 
40
41 Analysis and Statistics
42
43 All currents were analyzed using pClampFit 10 software (Molecular Devices) at 
44 minimum peak current during test pulse. In experiments studying agonist-evoked activity, 
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1 currents were normalized to the maximum value for each condition. In experiments studying 
2 basal currents, currents were normalized based on the capacitance of each cell, which 
3 represents the size of the cells. Representative traces of currents for each condition were 
4 plotted using OriginPro 9 software.
5 Black dots on figures represent individual data points, and bars with error bars 
6 display mean ± SEM. 
7 Statistical analysis was performed using GraphPad Prism 6 software. Kolmogorov–
8 Smirnov, Bartlett’s and Brown-Forsythe´s tests were used for population analysis. The 
9 statistical tests used for each data set are specified in figure legends. Statistical significance 
10 for all tests is 0.05. P-values above 0.05 were omitted. Concentration-response curves were 
11 fitted using the Hill equation, and parameter comparison was achieved with GraphPad. 
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